Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.
Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.
复制标题
DOI：
10.1371/journal.pone.0096384
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Hao KK
中科院分区：
文献类型：
--
作者：
Xu CH;Yu LK;Hao KK
本研究旨在探讨血清YKL-40水平与小细胞肺癌（SCLC）临床特征、化疗疗效及预后的关系。检测120例小细胞肺癌患者化疗前后血清YKL-40水平，并与40例健康对照组进行比较。采用受试者工作特征（ROC）曲线对小细胞肺癌进行诊断，并计算ROC曲线下面积。采用Kaplan-Meier法、单因素和多因素考克斯回归分析化疗前血清YKL-40水平与无进展生存期（PFS）和总生存期（OS）的相关性。化疗前血清YKL-40水平显著高于对照组（P<0.001）。SCLC病例中化疗后血清YKL-40水平低于这些病例中化疗前血清YKL-40水平（p = 0.026）。 高血清YKL-40患者对化疗的反应比低血清YKL-40患者差（p = 0.031）。 单变量分析显示，血清YKL-40水平高的SCLC患者的PFS和OS短于血清YKL-40水平低的患者（HR为1.74，p = 0.033; HR为1.33，p = 0.001）。 考克斯多变量分析表明，YKL-40是PFS和OS的独立预后指标（HR为1.12，p = 0.029; HR为1.84，p = 0.025）。 Kaplan-Meier生存曲线进一步证实，血清YKL-40水平较低的患者PFS和OS较长（分别为p= 0.016和p =0.041）。 这些结果表明YKL-40是SCLC化疗反应的潜在预后标志物。
This study was to explore the association between the serum YKL-40 level and the clinical characteristics, the response to chemotherapy and prognosis in small cell lung cancer (SCLC). Serum YKL-40 levels were detected and compared in 120 patients with SCLC pre- and post-chemotherapy, and in 40 healthy controls. Receiver operating characteristics (ROC) curves were adopted for diagnosis and calculation of area under ROC curve in SCLC. The Kaplan–Meier method, univariate and multivariate Cox regression analysis were used to analyze the correlation between pre-chemotherapy serum YKL-40 levels and progression-free survival (PFS) and overall survival (OS). The pre-chemotherapy serum YKL-40 levels were significantly higher than those of the controls (p<0.001). The post-chemotherapy serum YKL-40 levels in the SCLC cases were lower than pre-chemotherapy serum YKL-40 levels in these cases (p = 0.026). The patients with high serum YKL-40 showed a poorer response to chemotherapy than those patients with low serumYKL-40 (p = 0.031). Univariate analysis revealed that SCLC patients with high serum YKL-40 had a shorter PFS and OS than those with low serum YKL-40 (HR of 1.74, p = 0.033; HR of 1.33, p = 0.001). Cox multivariate analysis indicated that YKL-40 was an independent prognostic indicator of PFS and OS (HR of 1.12, p = 0.029; HR of 1.84, p = 0.025). Kaplan–Meier survival curves further confirmed that patients with low serum YKL-40 have longer PFS and OS (p = 0.016 and p = 0.041, respectively). These results suggest that YKL-40 is a potential prognostic marker of chemotherapy response in SCLC.
登录
查看更多内容
影响因子：
3.7
作者：
Schultz NA;Christensen IJ;Werner J;Giese N;Jensen BV;Larsen O;Bjerregaard JK;Pfeiffer P;Calatayud D;Nielsen SE;Yilmaz MK;Holländer NH;Wøjdemann M;Bojesen SE;Nielsen KR;Johansen JS
通讯作者：
Johansen JS
影响因子：
3.1
作者：
Tufman, Amanda;Huber, Rudolph Maria
通讯作者：
Huber, Rudolph Maria
影响因子：
2
作者：
Gronlund, B.;Hogdall, E. V. S.;Hogdall, C.
通讯作者：
Hogdall, C.
影响因子：
5.3
作者：
Free, C. M.;Ellis, M.;Baldwin, D. R.
通讯作者：
Baldwin, D. R.
DOI：
10.1084/jem.20081271
发表时间：
2009-05-11
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Lee CG;Hartl D;Lee GR;Koller B;Matsuura H;Da Silva CA;Sohn MH;Cohn L;Homer RJ;Kozhich AA;Humbles A;Kearley J;Coyle A;Chupp G;Reed J;Flavell RA;Elias JA
通讯作者：
Elias JA